SLC29A1 polyclonal antibody
* The price is valid only in USA. Please select country.
-
More Files
- More Functions
-
Specifications
Product Description
Rabbit polyclonal antibody raised against synthetic peptide of SLC29A1.
Immunogen
A synthetic peptide (conjugated with KLH) corresponding to internal region of human SLC29A1.
Host
Rabbit
Reactivity
Human, Mouse
Form
Liquid
Purification
Protein A purification
Recommend Usage
Western Blot (1:1000)
The optimal working dilution should be determined by the end user.Storage Buffer
In PBS (0.09% sodium azide)
Storage Instruction
Store at 4°C. For long term storage store at -20°C.
Aliquot to avoid repeated freezing and thawing.Note
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Applications
Western Blot (Transfected lysate)
Western blot analysis of ENT1 (SLC29A1) (arrow) using rabbit SLC29A1 polyclonal antibody (Cat # PAB2255). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the ENT1 (SLC29A1) gene (Lane 2) (Origene Technologies). -
Gene Info — SLC29A1
Entrez GeneID
2030Protein Accession#
NP_004946;Q99808Gene Name
SLC29A1
Gene Alias
ENT1, MGC1465, MGC3778
Gene Description
solute carrier family 29 (nucleoside transporters), member 1
Omim ID
602193Gene Ontology
HyperlinkGene Summary
This gene is a member of the equilibrative nucleoside transporter family. The gene encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene. [provided by RefSeq
Other Designations
OTTHUMP00000016506|OTTHUMP00000016507|OTTHUMP00000016508|OTTHUMP00000016509|OTTHUMP00000016510|OTTHUMP00000016511|OTTHUMP00000016512|equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-sensitive nucleoside transporter|equilibrative nucleoside transpo
-
Interactomes
-
Diseases
-
Publication Reference
-
Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma.
Erik R Peterson, Peter Sajjakulnukit, Andrew J Scott, Caleb Heaslip, Anthony Andren, Kari Wilder-Romans, Weihua Zhou, Sravya Palavalasa, Navyateja Korimerla, Angelica Lin, Alexandra O'Brien, Ayesha Kothari, Zitong Zhao, Li Zhang, Meredith A Morgan, Sriram Venneti, Carl Koschmann, Nada Jabado, Costas A Lyssiotis, Maria G Castro, Daniel R Wahl.
Cancer & Metabolism 2024 Apr; 12(1):11.
Application:WB, Human, H3k27m-isogenic cells.
-
"Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer.
Ornella Randazzo, Filippo Papini, Giulia Mantini, Alessandro Gregori, Barbara Parrino, Daniel S K Liu, Stella Cascioferro, Daniela Carbone, Godefridus J Peters, Adam E Frampton, Ingrid Garajova, Elisa Giovannetti.
Cancers 2020 Oct; 12(11):3206.
Application:IHC, Human, Human pancreatic ductal adenocarcinoma, Human pancreatic cancer.
-
Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Yabushita Y, Mori R, Taniguchi K, Matsuyama R, Kumamoto T, Sakamaki K, Kubota K, Endo I.
Anticancer Research 2017 May; 37(5):2465.
Application:IHC-P, Human, Human pancreatic cancer.
-
Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T.
British Journal of Cancer 2014 Sep; 111(7):1275.
Application:IHC-P, Human, Cholangiocarcinoma.
-
Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T.
Surgery 2012 Dec; 153(4):565.
Application:IHC-P, Human, Pancreatic carcinoma.
-
Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection.
Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Sueda T.
Annals of Surgical Oncology 2012 Jul; 19 Suppl 3:S646.
Application:IHC-P, Human, Pancreatic ductal adenocarcinoma.
-
Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: characterization of a novel nucleobase transporter.
Bone DB, Hammond JR.
American Journal of Physiology. Heart and Circulatory Physiology 2007 Dec; 293(6):H3325.
-
Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney.
Damaraju VL, Elwi AN, Hunter C, Carpenter P, Santos C, Barron GM, Sun X, Baldwin SA, Young JD, Mackey JR, Sawyer MB, Cass CE.
American Journal of Physiology. Renal Physiology 2007 Jul; 293(1):F200.
Application:IF, IHC-P, WB-Ti, Human, Human kidney.
-
Characterization and functional analysis of the promoter for the human equilibrative nucleoside transporter gene, hENT1.
Abdulla P, Coe IR.
Nucleosides, Nucleotides & Nucleic acids 2007 Jan; 26(1):99.
-
Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma.
- +1-909-264-1399
+1-909-992-0619
Toll Free : +1-877-853-6098 - +1-909-992-3401
- sales@abnova.com